Research progress of small molecule targeted drugs for non-small cell lung cancer - Takeaways - MDSpire

Research progress of small molecule targeted drugs for non-small cell lung cancer

  • By

  • Tingxiang Qiu

  • Xin Huang

  • July 15, 2026

Share

  • 1

    Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and has a poor prognosis with a 5-year survival rate of only 15%.

  • 2

    Molecular targeted therapy has become a cornerstone in the treatment of NSCLC, offering potent anti-tumor activity and a favorable safety profile.

  • 3

    Research has focused on small-molecule targeted agents against major oncogenes in NSCLC, including EGFR, ALK, and KRAS, among others.

  • 4

    Current targeted therapies face limitations such as acquired drug resistance and insufficient penetration across the blood-brain barrier.

  • 5

    Future research should prioritize the clinical translation of investigational drugs and explore combination treatment regimens to improve outcomes in NSCLC.

Original Source(s)

Research progress of small molecule targeted drugs for non-small cell lung cancer

  • by Tingxiang Qiu, Xin Huang

  • July 15, 2026

Related Content

Gut microbiota induces immune-related alterations in gene expression, RNA methylation, and metabolism in glioblastoma revealed by single-cell and spatial multi-omics

Non-bacterial cystitis following treatment with toripalimab for alpha-fetoprotein-producing gastric adenocarcinoma: a case report

EUS-guided transmural treatment of afferent loop syndrome: a systematic review and meta-analysis